Evan L. O'KEefe

Evan L. O'KEefe

Auto-generated profile, based on publicly available information

Evan L. O'KEefe

Saint Luke’s Mid America Heart Institute, Kansas City, MO (E.L.O.K., Y.J.C., P.G.J., J.A.S.).

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Stroke
Verified
Journal Article
Closed access
JOJames H. O’keefe
James H. O’keefe
NTNathan L. Tintle
Nathan L. Tintle
WHWilliam S. Harris
William S. Harris
EOEvan L. O’keefe
Evan L. O’keefe
ASAleix Sala-Vila
Aleix Sala-Vila
DMDariush Mozaffarian
Dariush Mozaffarian
BACKGROUND: The effect of marine omega-3 PUFAs on risk of stroke remains unclear. METHODS: We investigated the associations between circulating and tissue omega-3 PUFA levels and incident stroke (total, ischemic, and hemorrhagic) in 29 international prospective cohorts. Each site conducted a de novo individual-level analysis using a prespecified analytical protocol with defined exposures, covariates, analytical methods, and outcomes; the harmonized data from the studies were then centrally pooled. Multivariable-adjusted HRs and 95% CIs across omega-3 PUFA quintiles were computed for each stroke outcome. RESULTS: Among 183 291 study participants, there were 10 561 total strokes, 8220 ischemic strokes, and 1142 hemorrhagic strokes recorded over a median of 14.3 years follow-up. For eicosapentaenoic acid, comparing quintile 5 (Q5, highest) with quintile 1 (Q1, lowest), total stroke incidence was 17% lower (HR, 0.83 [CI, 0.76–0.91]; P <0.0001), and ischemic stroke was 18% lower (HR, 0.82 [CI, 0.74–0.91]; P <0.0001). For docosahexaenoic acid, comparing Q5 with Q1, there was a 12% lower incidence of total stroke (HR, 0.88 [CI, 0.81–0.96]; P =0.0001) and a 14% lower incidence of ischemic stroke (HR, 0.86 [CI, 0.78–0.95]; P =0.0001). Neither eicosapentaenoic acid nor docosahexaenoic acid was associated with a risk for hemorrhagic stroke. These associations were not modified by either baseline history of AF or prevalent CVD. CONCLUSIONS: Higher omega-3 PUFA levels are associated with lower risks of total and ischemic stroke but have no association with hemorrhagic stroke.

3 February 2025 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
WFWilliam G. Franco
William G. Franco
EOEvan L. O'KEefe
Evan L. O'KEefe
JOJames H. O'KEefe
James H. O'KEefe
NTNathan Tintle
Nathan Tintle
RMRoberto Marchioli
Roberto Marchioli
WWWilliam S William
William S William

1 April 2021 in Current Opinion in Psychology
Verified
Journal Article
Closed access
EOEvan L O’kEefe
Evan L O’kEefe
TPTyler M Peterson
Tyler M Peterson
CLCarl J Lavie
Carl J Lavie

6 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
EOEvan L O'Keefe
Evan L O'Keefe
JOJames H O’keefe
James H O’keefe
NTNathan Tintle
Nathan Tintle
WFWilliam Grant Franco
William Grant Franco
JWJason Westra
Jason Westra
WWWilliam S William
William S William
Objective: To determine the relationship between plasma omega-3 levels and incident atrial fibrillation (AF), and the association between fish oil supplement (FOS) use and risk for AF. Methods and Analysis: Recent studies in UK Biobank concluded that FOS use was associated with increased risk of incident AF. Conversely, a meta-analysis found inverse relationships between blood levels of omega-3 and AF risk. We performed a prospective observational study linking plasma omega-3 levels and reported FOS use with AF risk in UK Biobank. Among UK Biobank participants without prevalent AF, 261 108 had plasma omega-3 levels and 466 169 reported FOS use. The primary outcome was incident AF during follow-up (median 12.7 years). Multivariable-adjusted hazard ratios (HR, 95% confidence intervals, CI) for fatty acids were computed continuously (per inter-quintile range, IQ 5 R) and by quintile. Hazard ratios were computed for dichotomous fish oil supplement use. Results: Plasma omega-3 levels were inversely associated with incident AF (HR per IQ 5 R = 0.90, 95% CI 0.86, 0.93; HR=0.87 [0.83, 0.91] in quintile 5 vs quintile 1). Fish oil supplement use was reported by 31% of the cohort and was more common in older individuals. After adjusting for age as a continuous variable, no association was observed between fish oil supplement use and AF risk (HR=1.00; 95% CI 0.97, 1.02). Conclusion: Higher circulating omega-3 levels were linked to reduced AF risk in UK Biobank. Further, after age was adjusted for as a continuous variable, no association was found between fish oil supplement use and AF.

1 September 2026 in Circulation: Population Health and Outcomes
Verified
Journal Article
Closed access
EOEvan L. O’KEefe
Evan L. O’KEefe
JSJohn T. Saxon
John T. Saxon
YCYoon Joo Cho
Yoon Joo Cho
PJPhilip G. Jones
Philip G. Jones
DMDaniel B. Mark
Daniel B. Mark
HSHemalata Siddaram
Hemalata Siddaram
BACKGROUND: Patient-centered prognostic assessment in chronic coronary disease is vital for treatment optimization. Although the Seattle Angina Questionnaire Summary Score (SAQ-SS) correlates with clinical outcomes, clinicians lack guidance on how to weigh prior, current, or changes in scores, and whether prognostic significance varies by revascularization strategy. METHODS: The ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches; 2012–2019) was a global, multicenter, randomized controlled trial. This secondary analysis evaluated the prognostic value of serial SAQ-SS assessments. The SAQ-SS ranges from 0 to 100, with higher scores indicating better health status. To simulate routine clinical care, the follow-up in ISCHEMIA was equated to outpatient clinic visits—we defined the 3-month SAQ-SS as the prior score and the 6-month assessment as the current score in the clinic. Analyses were stratified by treatment strategy: conservative management and invasive management with revascularization. Cox proportional hazards models assessed the association of the prior score, the current score, and the change in scores with ISCHEMIA’s primary composite end point (cardiovascular death, myocardial infarction, hospitalization for unstable angina, heart failure, and resuscitated cardiac arrest), adjusting for 17 clinical covariates. RESULTS: This analysis included 3405 participants (1965 in conservative management: 77.4% male, mean age 64.3 years±9.5; 1440 in invasive management: 77.6% male, mean age 64.0 years±9.4). Over a median follow-up of 3.2 years, 215 (11.0%) and 96 (6.7%) participants in the conservative and invasive cohorts, respectively, experienced the primary composite end point. Higher prior, current, and change SAQ-SS were each independently associated with a lower risk of cardiovascular events. In the conservative cohort, each 5-point increase in the current SAQ-SS was associated with a 7% lower risk of the primary end point (hazard ratio, 0.93 [95% CI, 0.90–0.96]); in the invasive cohort, the association was 9% (hazard ratio, 0.91 [95% CI, 0.86–0.96]). CONCLUSIONS: In patients with chronic coronary disease, the most recent SAQ-SS is the strongest health status predictor of future cardiovascular events. Serial SAQ-SS assessments provide a practical, dynamic, and patient-centered approach for updating prognosis in chronic coronary disease management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01471522.

1 March 2020 in American Medical Student Research Journal
Verified
Journal Article
Open access
PDF file
EOEvan L O'Keefe
Evan L O'Keefe
NTNoel Torres-Acosta
Noel Torres-Acosta
JOJames H O'Keefe
James H O'Keefe
Neckties on Physicians: Going the Way of Powdered Wigs